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ABSTRACT 
---------------------------------------------------------------------------------------------------------- 
The synthesis of RNA molecules carrying lipids at their 3’-termini and 5’-termini is 
reported. These conjugates were fully characterized by MALDI-TOF mass spectrometry 
and HPLC chromatography. The ability of these conjugates to silence gene expression 
was evaluated in the inhibition of the tumor necrosis factor. All the lipid-siRNA 
derivatives were compatible with RNA interference machinery if transfected with 
oligofectamine. In the absence of a transfection agent some lipid-siRNA derivatives can 
exert a slight reduction of gene expression. 
---------------------------------------------------------------------------------------------------------- 
 
Introduction.- Many years ago the use of modified nucleic acids to inhibit gene 
expression by blocking translation and transcription or by stimulating the degradation of 
a particular messenger RNA (mRNA) became a promising approach in therapy. This 
process uses antisense technology [1-3] and, more recently, RNA interference (RNAi) 
[4]. Although both strategies inhibit the same stage of translation of a gene to a protein, 
their mechanisms are different. In the case of antisense technology, synthetic 
oligonucleotides are designed to selectively bind to the complementary mRNA 
transcript of a targeted gene thereby inhibiting mRNA translation to the corresponding 
protein [5]. In contrast the RNAi approach uses short double-stranded RNA (dsRNA) 
molecules to switch genes off. Components of the RNAi machinery specifically 
recognize the short interfering duplex RNAs (siRNA) and incorporate the guide RNA 
strand into a protein complex named the RNA-induced silencing complex (RISC). The 
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complex formed by the guide RNA strand and RISC catalyzes the degradation of a 
specific mRNA, thereby repressing the synthesis of a specific protein [6-7]. However, 
the use of oligonucleotides in both therapies is inefficient, since they are rapidly 
degrated by exonucleases and endonucleases in physiological conditions, and also 
because of their poor cellular uptake, which is primarily due to their relatively large 
molecular weight and their polyanionic nature. The lack of solutions to these two 
problems (especially in the case of cellular uptake), have caused a bottleneck in the 
development of nucleic acids in potential therapeutics [8].  
In order to enhance the stability of oligonucleotides to nuclease degradation and 
increase cellular uptake a major research effort is being made to design and synthesize 
modified nucleic acids with similar hybridization properties but improved biological 
properties [9-11]. The synthesis of modified nucleic acids such as phosphorothioate 
[12], methyl phosphonate [13] and phosphoramidate oligonucleotides [14] locked 
nucleic acids [15] or peptide nucleic acids [16] has efficiently improved the stability of 
oligonucleotides in serum. On the issue of delivery progress has been made in the 
development of new non-viral carriers such as polymers [17], lipids [18], cell-
penetrating peptides [19] or nanoparticles [20] for oligonucleotide delivery. However, 
despite considerable research, efficiency and specificity results are still not satisfactory 
in many cases. To date, most of the strategies for improving cellular uptake use carriers 
that can be covalently linked to ODNs using the post-synthetic conjugation [21-24] 
method or through the preparation of complexes (lipoplexes, polyplexes) [25-28]. The 
formation of these complexes is due to the existence of electronic interactions between 
polyanionic nucleic acids and the positively charged nature of the designed carrier. In 
particular, the conjugation of lipids to siRNA, such as cholesterol and fatty acids, 
produces molecules with improved inhibitory properties [29-32]. 
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As part of our ongoing interest in gene-silencing methods [33-34] and in finding 
new carriers to improve inhibition and cellular uptake, we now propose a simple 
strategy in which several lipid tails are covalently linked to oligonucleotides at their 3’-
end (using controlled pore glass (CPG) supports) or at 5’-end (phosphoramidite 
chemistry) (Figure 1). The target lipid molecules are based on the lipids that are used to 
formulate the stable nucleic acid-lipid particles (SNALP) [35-36] for the systemic 
administration of siRNA [37-38]. We studied the silencing properties of the conjugates 
carrying the lipid modification in the passenger strand of the siRNA. Our target for 
RNAi studies is the tumor necrosis factor (TNF-α) gene. The protein is involved in 
several biological processes such as apoptosis, inflammation and immunity and it has 
been implicated in the pathogenesis of many human diseases. The inhibition of this 
cytokine is of particular relevance for the development of anti-inflammatory drugs [24]. 
Figure 1 
 
Results and Discussion.- 1. Synthesis of lipid derivatives. We considered the 
use of a glycerol backbone based structure to be a suitable scaffold for introducing our 
chemical modifications, covalently linked to oligonucleotides at their 3’-end. This 
strategy was successfully used to introduce the 1-O-hexyldecylglycerol unit into 
antisense DNA [39]. The synthesis is outlined in Scheme 1. To prepare oligonucleotides 
carrying lipids C14 and C18 at the 3’-position, controlled pore glass (CPG) supports were 
functionalized by reaction of the suitable trityl-lipid derivatives 4 or 9 with amino-
functionalized CPG prior to DNA/RNA synthesis. To synthesize 4, the alkylation 
reaction between commercially available solketal 1 and 1-bromotetradecane with 
sodium hydride (60%) in the presence of toluene was carried out to yield the respective 
alkylated compound 2. Acetonide hydrolysis (pTsOH, MeOH) yielded the expected diol 
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3, which was selectively protected using the 4-monomethoxy trityl (MMTr) group. This 
reaction provided the desired trityl-protected alcohol 4 at a high yield. We used a 
similar synthetic route for the synthesis of trityl alcohol 9. Mesylate 6 was used in the 
alkylation reaction instead of a bromo derivative. Then, compounds 7, 8 and 9 were 
prepared in good yields and were fully characterized. Finally, with the two synthesized 
trityl compounds 4 and 9 on hand, we coupled them to CPG supports using the succinyl 
linker described in the literature [40-41]. CPG functionalization yielded glass beads that 
were loaded with our proposed lipids containing 5 (15 µmol/g) and 10 (16 µmol/g), 
respectively.  To introduce lipids C28 and C14N at the 5’-position, we used the 
phosphoramidite approach (Scheme 2). For the synthesis of lipid phosphoramidite 15; 
the selective protection of commercially available primary alcohol 11 with trityl 
chloride was carried out according to the literature [42]. Then, protected alcohol 12 was 
subjected to an alkylation reaction using 1-bromotetradecane in the presence of THF, 
which resulted in alkylated-trityl derivative 13 at a high yield. Subsequently, trityl 
deprotection under acid conditions (DCM:TFA 20%) easily produced alcohol 14 which 
was transformed into the desired phosphoramidite 15. This was then directly used for 
the synthesis of oligonucleotides without further purification.  
Scheme 1 
Lipophosphoramidite 19 was synthesized by a double alkylation reaction of 
commercially available protected triol 16 and 1-bromotetradecane, according to the 
literature [36]. The removal of the allyl group of compound 17 with Pd[(PhP)3]4 in the 
presence of THF yielded the desired alcohol 18, which was subsequently transformed 
into its phosphoramidite derivative 19. As in the previous case, phosphoramidite 19 was 
used for DNA / RNA synthesis without further purification. 
Scheme 2 
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2. Synthesis of oligodeoxynucleotide-lipid conjugates. Solid supports and 
phosphoramidites that have been previously described were used for the preparation of 
oligonucleotides carrying lipids at the 3’ or 5’-ends. We selected the self-
complementary oligodeoxynucleotide sequence 5’-d(CGCGAATTCGCG)-3’ known as 
the Dickerson-Drew dodecamer, as a model compound. Oligonucleotide sequences 
were assembled on a DNA synthesizer using standard protocols. After the assembly of 
the desired DNA sequence, supports were treated with concentrated ammonia at 55ºC 
for a minimum of 6 hrs to yield oligonucleotides 20-23 carrying lipid molecules at the 
3’- or 5’-ends. In all cases a major peak was obtained that had the expected molecular 
weight as determined by MALDI-TOF mass analysis (experimental section). This 
indicates that the oligonucleotide-lipid conjugates are stable to oligonucleotide synthesis 
conditions. 
 
2. Lipid-siRNA conjugates. Next the synthesis of lipid conjugates of RNA was 
studied. We selected a previously described siRNA duplex to inhibit the expression of 
the TNF-a gene [43]. These siRNA are being studied as potential anti-inflammatory 
drugs. RNA conjugates of passenger strands carrying lipids at the 3’- and 5’-end were 
prepared (Table 1). A siRNA duplex carrying a cholesterol molecule at the 3’-end of the 
passenger strand was also prepared for comparison purposes. Finally, RNA conjugates 
of the guide strand carrying lipids C14 and C18 at the 3’-end of the guide strand were 
prepared (Table 1). Syntheses were carried out using standard RNA synthesis protocols 
and RNA monomers carrying the tert-butyldimethylsilyl (TBDMS) group in the 2’-
position. RNA conjugates carrying lipids at the 3’-position were purified using DMT-on 
protocols whereas RNA conjugates carrying lipids at the 5’-position were purified 
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according to DMT-off protocols. All modified conjugates were purified by 
semipreparative HPLC chromatography. In all cases we obtained a major peak that was 
isolated and characterized by MALDI- TOF mass spectrometry (see Table 1). All 
conjugates were annealed with equimolar amounts of the unmodified guide strands and 
purified from EtOH precipitation (Table 1). 
Table 1 
We examined the effect of the lipids on siRNA duplex stability. The thermal 
stability of the modified and unmodified duplexes was measured in 100 mM potassium 
acetate, 2 mM magnesium acetate, and 30 mM HEPES-KOH at pH 7.4 (Table 2). The 
melting curves of the duplexes were virtually identical (83.9ºC, 83.6ºC, 84.3ºC; for 
siRNA-3, siRNA-5 and siRNA-6, respectively) compared to the siRNA-1 wild type 
(83.5ºC), except for siRNA-4, which stabilized slightly when hybridized to its 
complement (86.9ºC, with ΔTm = 3.4 ºC). This was probably due to the presence of 2’-
OMe groups in the pyrimidines of the RNA molecule [44] (Table 2). These results 
indicate that the presence of lipid groups at the 3 and 5’-position of the siRNA molecule 
does not affect their ability to form stable duplexes.  
Figure 2 
Next, we studied the TNF-α inhibitory properties of the lipid-modified siRNA 
duplexes [40] using two different series of experiments. In the first case, siRNA 
transfection was carried out using commercially available cationic lipid 
(oligofectamine). To this end, HeLa cells were first transfected with plasmid expressing 
murine TNF-α using lipofectin. One hour later, unmodified siRNA-1 or lipid-modified 
siRNA conjugates in the passenger strand (siRNA-2, siRNA-3, siRNA-4, siRNA-5, 
siRNA-6 and siRNA-7, respectively at 50 nM) as well as the scrambled sequence Scr 
were co-transfected using Oligofectamine. Cells were analyzed using an enzyme-linked 
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immunoabsorbent assay (ELISA) after twenty four hours of transfection. Inhibition 
results are depicted on Figure 2. Unmodified and modified siRNA conjugates at the 3’-
position (siRNA-2, siRNA-3, siRNA-4 and siRNA-5) showed 90-95% inhibition of the 
TNF-α production compared to the scrambled control Scr duplex. The inhibition results 
for the modified siRNA conjugates at the 5’-position were somewhat lower (80% and 
60% for siRNA-6 and siRNA-7, respectively). Although we obtained better inhibition 
results for modified siRNA conjugates at the 3’-position, in general, the introduction of 
the lipid modifications did not disrupt the RNAi machinery. After verifying the 
functionality of our modifications, we evaluated whether the presence of the lipid 
modifications in siRNA duplexes could improve the cellular uptake process. After 
transfecting HeLa cells with the murine TNF-a plasmid, the cells were treated with 
unmodified and modified siRNA conjugates (siRNA-1, siRNA-2, siRNA-3, siRNA-4, 
siRNA-5 and siRNA-6 at 100 nM) in the absence of a transfection agent (Figure 3). The 
inhibition activity of TNF-α is much lower in this case, due to the absence of 
Oligofectamine. However, some chemically modified siRNAs silenced the TNF-α gene 
expression with promising inhibitory results (19%, 17% and 38% for siRNA-5, siRNA-
6 and siRNA-7, respectively) compared to the scrambled siRNA duplex (siRNA 8). 
Surprisingly, the most active siRNA without a transfecting agent is the less active 
siRNA with oligofectamine. These results indicate that the most interesting siRNA 
derivative prepared in this work was the siRNA-7, which carries the C28 lipid at the 5’-
end.  
Figure 3 
The inhibitory properties of siRNA duplexes carrying lipids at the guide strand 
(siRNA-9, siRNA-10) were also analyzed (Figure 4). Lipid-modified (siRNA-9, 
siRNA-10) and unmodified siRNA (siRNA-1)  against TNF-a produced an 80-90% 
 9
inhibition of the production of TNF-a compared with the scrambled control siRNA 
duplex (siRNA 8). These results indicate that the introduction of the lipid at the 3’-end 
of either the guide or the passenger strand of an RNA duplex does not affect the 
inhibitory properties of the resulting siRNA duplex in HeLa cells.  
Figure 4 
 
Conclusions. 
In summary, we have reported an efficient strategy for introducing novel lipid moieties 
at the 3’- and 5’-position of DNA and RNA molecules through covalent bonds that are 
stable to oligonucleotide synthesis conditions.  The effect of these modifications on the 
cellular activity does not interfere with the RNAi machinery. In the presence of a 
transfection agent, we observed better RNAi inhibitory properties with siRNA 
conjugates carrying lipids at the 3’-termini.  However, in the absence of transfection 
agent, we observed better cellular uptake when the lipid C28 was attached at the 5’-
position of the passenger strand. These promising results will be followed up with more 
detailed cellular uptake studies using these conjugates as well as the use of non-viral 
carriers to improve gene delivery.   
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Materials and Methods. All reactions were carried out under argon positive pressure in 
anhydrous solvents. Commercially available reagents and anhydrous solvents were used 
without further purification. Solvents were distilled prior to use and dried using standard 
methods. Analytical samples were homogeneous, as confirmed by TLC, and yielded 
spectroscopic results that were consistent with the structures assigned. Chemical shifts 
are reported in parts per million (ppm) relative to the singlet at δ = 7.24 ppm of CHCl3 
for 1H NMR and to the centre line of the triplet at δ = 77.0 ppm of CDCl3 for 13C NMR. 
IR spectra were measured on film and were recorded with a BOMEM MB-120. Thin-
layer chromatography (TLC) was performed on silica gel (Alugram Sil G/UV). MALDI 
mass spectrometry was recorded on a Fisons VG Tofspec spectrometer and ESI mass 
spectra on a Fisons VG Platform II spectrometer. Oligonucleotide sequences were 
prepared using solid phase methodology on an Applied Biosystems Model 3400 DNA 
synthesizer. Oligoribonucleotides were purified by DMT-on protocols using reversed-
phase HPLC. 
HPLC conditions. Conditions for semipreparative HPLC were as follows. HPLC 
solutions were solvent A: 5% acetonitrile (ACN) in 100 mM triethylammonium acetate 
(TEAA), pH 6.5; and solvent B: 70 % ACN in 100 mM triethylammonium acetate (pH 
6.5). Column: PRP-1 (Hamilton) 250 x 10 mm. A flow rate 3 ml/min linear gradient 
from 15 to 100% in B (DMT-on) and 0 to 50% in B (DMT-off) was used with UV 
detection at 260 nm. 
General procedure for the alkylation reaction. Solketal 1 (100 mg, 0.757 mmol) and 
60% sodium hydride (NaH, 60.4 mg, 1.51 mmol, 2.0 eq) were stirred in toluene (3.0 
mL) under argon for 20 minutes. The corresponding alkyl bromide C14 (420 mg, 1.51 
mmol, 2.0 eq) or mesylate C18 (520 mg, 1.51 mmol) was dissolved in toluene (2.0 mL) 
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and added dropwise. The reaction was refluxed under argon overnight. It was then 
diluted with more toluene (10 mL) and the reaction mixture was cooled in an ice bath 
while quenched via the slow addition of cold water. The mixture was washed with water 
(5 mL) and brine (5 mL), using ethanol to aid phase separation if necessary. The organic 
phase was dried over anhydrous sodium sulphate and evaporated. The crude product 
was purified by flash chromatography (Ch:AcOEt 0% to 3%). 
2,2-dimethyl-4-(tetradecyloxymethyl)-1,3-dioxolane, 2. Yield: 78%; IR (film) 2925, 
2854, 1462, 1379, 1370, 1117.4 cm-1; 1H-NMR (400 MHz, CDCl3) δ 4.26 (q, J = 6.0 
Hz, 1H), 4.05 (dd, J = 8.2 Hz, 6.4 Hz; 1H), 3.73 (dd, J = 8.2 Hz, 6.4 Hz; 1H), 3.51 (m, 
2H), 3.43 (m, 2H), 1.60 (m, 4H), 1.42 (s, 3H), 1.36 (s, 3H), 1.25 (m, 20H), 0.88 (t, J = 
6.6 Hz, 3H); 13C-NMR (400 MHz, CDCl3) δ 109.6, 74.9, 72.1, 72.0, 67.1, 32.1, 30.0, 
29.9, 29.8, 29.8, 29.8, 29.8, 29.7, 29.6, 29.5, 26.9, 26.2, 25.6, 22.9, 14.3; HR ESI MS: 
m/z calculated for C20H40 Na O3 (M+ + 23), 351.2870, found m/z 351.2862; calculated 
for C40H80 Na O6 (2M+ + 23), 679.5847, found m/z 679.5835. 
2,2-dimethyl-4-(((10Z,13Z)-octadeca-10,13-dienyloxy)methyl)-1,3-dioxolane, 7. Yield: 
77%; IR (film) 3008, 2986, 2926, 2856, 1457, 1379, 1369, 1214, 1120, 847 cm-1; 1H-
NMR (400 MHz, CDCl3) δ 5.34 (m, 4H), 4.25 (q, J = 5.8 Hz, 1H), 4.04 (dd, J = 14.6 
Hz, 8.2 Hz, 1H), 3.71 (dd, J = 14.6 Hz, 8.2 Hz, 1H), 3.45 (m, 4H), 2.76 (t, J = 5.8 Hz, 
2H), 2.00 (m, 4H), 1.56 (m, 2H), 1.41 (s, 3H), 1.35 (s, 3H), 1.29 (m, 20H), 0.88 (t, J = 
6.8 Hz, 3H); 13C-NMR (400 MHz, CDCl3) δ 132.1, 128.9, 110.0, 72.7, 72.1, 70.5, 64.5, 
32.1, 30.0, 29.9, 29.8, 29.8, 29.8, 29.6, 29.5, 26.3, 22.9, 14.3; HR ESI MS: m/z 
calculated for C24H44 Na O3 (M+ + 23), 403.3183, found m/z 403.3176. 
General procedure for the deprotection reaction. A solution of alkylated compound 2 
(1.0 eq) and alkylated compound 7 (1.0 eq) along with p-toluenesulphonic acid 
monohydrate (0.5 eq) in methanol (5.0 mL) was stirred at room temperature overnight. 
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The solvent was evaporated and the residue was purified by flash chromatography, 
eluted with DCM:MeOH 0% to 2%. 
3-(tetradecyloxy)propane-1,2-diol, 3. Yield: 72%; IR (film) 2980, 2850, 2390, 2387 cm-
1; 1H-NMR (400 MHz, CDCl3) δ 3.87 (m, 1H), 3.74 (dd, J = 11.4 Hz, 3.9 Hz, 1H), 3.67 
(dd, J = 11.4 Hz, 5.0 Hz, 1H), 3.54 (m, 2H), 3.48 (m, 2H), 1.60 (m, 4H), 1.27 (m, 20H), 
0.89 (t, J = 6.8 Hz, 3H); 13C-NMR (400 MHz, CDCl3) δ 72.8, 72.0, 70.5, 64.5, 32.1, 
30.0, 29.9, 29.8, 29.8, 29.8, 29.6, 29.5, 26.3, 22.9, 14.3; HR ESI MS: m/z calculated for 
C17H36 Na O3 (M+ + 23), 311.2557, found m/z 311.2555. 
3-((10Z,13Z)-octadeca-10,13-dienyloxy)propane-1,2-diol, 8. Yield: 70 %; IR (film) 
3105, 2990, 2365, 1530, 1329 cm-1; 1H-NMR (400 MHz, CDCl3) δ 5.33 (m, 4H), 3.83 
(m, 1H), 3.64 (m, 2H), 3.47 (m, 4H), 2.74 (m, 2H), 2.01 (m, 4H), 1.55 (m, 2H), 1.27 (m, 
18H), 0.86 (t, J = 6.8 Hz, 3H); 13C-NMR (400 MHz, CDCl3) δ 130.4, 130.3, 130.2, 
130.2, 128.2, 128.1, 128.1, 128.0, 72.6, 72.5, 72.0, 72.0, 70.8, 70.7, 64.4, 64.3, 31.8, 
31.7, 29.9, 29.8, 29.7, 29.7, 29.7, 29.6, 29.6, 29.5, 29.5, 29.4, 29.4, 29.4, 27.4, 26.3, 
26.2, 25.8, 25.8, 22.8, 22.7, 14.3; HR ESI MS: m/z calculated for C21H40 Na O3 (M+ + 
23), 363.2698, found m/z 363.2697. 
General procedure for protection with MMTr. Diols 3 or 8 (1.0 eq) were co-evaporated 
twice with pyridine and dissolved again in pyridine (2 mL). DMAP (0.1 eq) and MMTr-
Cl (1.5 eq) were added at room temperature and the corresponding mixtures were stirred 
at 40ºC overnight. The reaction was quenched by addition of MeOH (5 mL). The crudes 
were concentrated in vacuo and the residues were purified by flash chromatography 
(DCM:MeOH:TEA 98:1:1). 
1-((4-methoxyphenyl)diphenylmethoxy)-3-(tetradecyloxy)propan-2-ol,4. Yield: 80%; IR 
(film) 3200, 1630, 1521, 1232, 990 cm-1; 1H-NMR (400 MHz, CDCl3) δ 7.37 (m, 2H), 
7.23 (m, 5H), 7.19 (m, 5H), 6.77 (m, 1H), 6.74 (m, 1H), 3.86 (m, 1H), 3.73 (s, 3H), 3.46 
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(dd, J = 9.7 Hz, 4.2 Hz, 1H), 3.39 (dd, J = 9.7 Hz, 6.4 Hz, 1H), 3.35 (m, 2H), 3.11 (m, 
2H), 2.34 (broad d, 1H), 1.47 (m, 2H), 1.19 (m, 22H), 0.81 (t, J = 6.6 Hz, 3H); 13C -
NMR (400 MHz, CDCl3) δ 158.9, 158.7, 150.0, 147.3, 144.6, 135.7, 130.5, 129.4, 
128.7, 128.6, 128.1, 128.0, 128.0, 127.3, 127.1, 123.9, 113.4, 113.3, 86.5, 81.9, 72.2, 
71.8, 70.1, 64.7, 55.4, 55.4, 32.1, 30.0, 29.9, 29.8, 29.8, 29.8, 29.7, 29.5, 26.3, 22.9, 
14.3; HR ESI MS: m/z calculated for C38H54 Na O5 (M+ + 23), 613.7623, found m/z 
613.7622. 
1-((4-methoxyphenyl)diphenylmethoxy)-3-((10Z,13Z)-octadeca-10,13-ienyloxy)propan-
2-ol, 9. Yield: 67%; IR (film) 3300, 2980, 2732, 1600, 1475, 1200, 995 cm-1; 1H-NMR 
(400 MHz, CDCl3) δ 7.57 (m, 1H), 7.36 (m, 2H), 7.20 (m, 7H ), 7.10 (d, J = 8.8 Hz, 
2H), 6.75 (d, J = 8.8 Hz, 2H), 5.29 (m, 4H), 3.87 (m, 1H), 3.70 (s, 3H), 3.45 (dd, J = 9.7 
Hz, 4.2 Hz, 1H), 3.37 (m, 1H), 3.10 (m, 2H), 3.01 (m, 2H), 2.69 (t, J = 6.5 Hz, 2H), 
2.42 (broad d, 1H), 1.96 (m, 2H), 1.46 (m, 2H), 1.20 (m, 18H), 0.80 (t, J = 6.7 Hz, 3H); 
13C -NMR (400 MHz, CDCl3) δ 158.8, 149.9, 147.4, 144.6, 139.5, 136.1, 130.5, 129.4, 
128.6, 128.1, 128.0, 128.0, 127.3, 127.1, 123.9, 113.4, 86.5, 81.9, 72.3, 71.8, 70.1, 64.7, 
55.4, 31.7, 29.9, 29.9, 29.8, 29.7, 29.6, 29.5, 27.5, 27.4, 26.3, 25.8, 22.8, 14.3; HR ESI 
MS: m/z calculated for C42H58 Na O5 (M+ + 23), 665.8249, found m/z 665.8250. 
General procedure for functionalization of CPG solid supports, 5 and 10. MMTr-
protected alcohols 4 or 9 along with DMAP (1.5 eq) and succinic anhydride (1.5 eq) 
were dissolved in dichloromethane (1 mL). Reactions were stirred overnight at room 
temperature. Dichloromethane was added (5 mL) and the organic layers were then 
washed with a 0.1M Na2HPO4 solution. The resulting organic layers were dried on 
sodium sulphate and the solvent was evaporated. The residues were used in the next 
step without further purification. 2,2-Dithio-bis-(5-nitropyridine) (0.1 mmol) dissolved 
in 400 μL of acetonitrile was mixed with a solution of the appropriate MMTr-protected 
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compounds (0.1 mmol) and DMAP (0.1 mmol) in acetonitrile (500 μL). A solution of 
TPP (0.1) dissolved in acetonitrile (200 μL) was added to the respective clear solutions 
at room temperature. The mixtures were then vortexed for a few seconds and added to a 
syringe containing LCAA-CPG (500 mg, 0.05 mmol amino groups). They were allowed 
to react for 2 hours at room temperature. The reactions were arrested by adding 
methanol (500 μL). The supports were then washed with methanol (3 x 10 ml), 
acetonitrile (3 x 10 mL) and diethyl ether (3 x 10 mL). The solid supports were dried in 
vacuo and then subjected to capping of the residual amino functionalities with a mixture 
of acetic anhydride/pyridine/tetrahydrofurane (500 μL) and 1-methylimidazole in 
tetrahydrofurane (500 μL). After 30 minutes, the resins were washed with methanol (3 x 
10 mL), acetonitrile (3 x 10 mL) and diethyl ether (3 x 10 mL). The solid supports 5 and 
10 were dried first in the air and then under high vacuum. Loading (5a) (μmol/g) = 15; 
loading (10) (μmol/g) = 16. 
N,N-dimethyl-2-(tetradecyloxy)-3-(trityloxy)propan-1-amine, 13. Protected alcohol 12 
(300 mg, 0.830 mmol) and 60 % NaH (133 mg, 3.32, 4.0 eq) were suspended in 
anhydrous THF (4.5 mL) and stirred for 15 min at room temperature. Alkyl bromide 
(575 mg, 2.1 mmol, 2.0 eq) was added dropwise. The reaction was heated to reflux 
overnight. It was then cooled at 0ºC and water (1.5 mL) was added carefully. The 
solvent was evaporated and the residue was dissolved in dichloromethane (10 mL), 
washing the organic layer with water (2 x 20 mL) and brine (2x 20 mL). The organic 
layer was dried on sodium sulphate and the solvent was evaporated. Crude was purified 
by flash chromatography (Ch:TEA 99:1 à Ch:AcOEt:TEA 98:1:1). 
Yield: 77%; IR (film) 3059, 2924, 2853, 2818, 2766, 1490, 1449, 1074, 909 cm-1; 1H-
NMR (400 MHz, CDCl3) δ 7.39 (m, 4H), 7.19 (m, 11H), 3.45 (m, 1H), 3.38 (m, 2H), 
3.08 (m, 2H), 2.31 (s, 6H), 1.49 (m, 2H), 1.18 (m, 22H), 0.81 (t, J = 6.6 Hz, 3H); 13C-
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NMR (400 MHz, CDCl3) δ 144.4, 128.9, 127.9, 127.1, 86.7, 77.9, 70.7, 70.6, 64.9, 61.7, 
60.2, 46.5, 45.7, 32.1, 30.4, 30.0, 29.9, 29.8, 29.6, 26.4, 22.9, 14.4; HR ESI MS: m/z 
calculated for C38H56 NO2 (M+ + H), 558.4306, found m/z 558.4298. 
3-(dimethylamino)-2-(tetradecyloxy)propan-1-ol, 14. Alkylated alcohol 13 (358 mg, 
0.642 mmol) was dissolved in a mixture of 20 % TFA in DCM (2:8). The reaction was 
stirred for two hours at room temperature. The organic layer was carried to basic pH 
with 1M NaOH solution and was extracted three times with dichloromethane (20 mL). 
The organic layer was dried with sodium sulphate and the solvent was evaporated. The 
residue was purified by flash chromatography (DCM:MeOH:TEA 90:9:1). 
Yield: 76%; IR (film) 3110, 2960, 2874, 1530, 1470, 1065, 864 cm-1; 1H-NMR (400 
MHz, CDCl3) δ 3.79 (dd, J = 10.9 Hz, 4.1 Hz, 1H), 3.68 (m, 1H), 3.48 (m, 5H), 2.60 
(m, 2H), 2.32 (s, 6H), 1.54 (m, 2H), 1.25 (m, 20H), 0.88 (t, J = 6.6 Hz, 3H); 13C-NMR 
(400 MHz, CDCl3) δ 75.3, 70.1, 65.6, 62.9, 46.5, 32.1, 30.3, 29.9,29.8, 29.8, 29.8, 29.8, 
29.6, 29.5, 26.3, 22.9, 14.3; HR ESI MS: m/z calculated for C19H41NO2 (M+ + H), 
316.2143, found m/z 316.2142. 
2,3-bis(tetradecyloxy)propan-1-ol, 18. A mixture of protected alcohol 17 (100 mg, 
0.191 mmol), N, N- dimethylbarbituric acid (80 mg, 0.514 mmol, 2.7 eq) and 
Pd[(PPh3)]4 catalyst (12.3 mg, 0.011 mmol, 0.05 eq) was dissolved in anhydrous THF 
(2.5 mL) and heated at 90ºC in a sealed-tube overnight. The solvent was evaporated and 
the residue was purified by flash chromatography (DCM:MeOH 0% to 1%) to yield a 
white solid. 
Yield: 97%; 1H-NMR (400 MHz, CDCl3) δ 3.72 (m, 1H), 3.61 (m, 2H), 3.50 (m, 2H), 
3.30 (m, 2H), 2.91 (m, 2H), 2.15 (m, 2H), 1.54 (m, 8H), 1.26 (m, 12H), 0.88 (t, J = 6.88 
Hz, 6H). 
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General procedure for the synthesis of lipo-phosphoramidites 14 and 19. 
Diisopropylethylamine (2 eq) was added dropwise at room temperature to a solution 
formed by alcohol 14, or 18 (1 eq) in DCM (2 mL). Subsequently, DCM solutions were 
cooled at 0ºC and β-cyanoethyl-N, N-diisopropylaminophosphochloride (1.0 eq) was 
added. The resulting reactions were removed from the ice bath and allowed to warm to 
room temperature, with stirring after 2 hours. The reactions were diluted with more 
dichloromethane (10 mL) and extracted with 10 mL of cold 0.5 M sodium bicarbonate. 
The organic layers were dried with anhydrous sodium sulphate and evaporated to leave 
a clear colourless syrup. A vacuum pump was used to remove the last traces of solvent 
and diisopropylethylamine. The resulting products were used without further 
purification. 
2-cyanoethyl 3-(dimethylamino)-2-(tetradecyloxy)propyl diisopropylphosphoramidite, 
15. Yield: 69%; 1H-NMR (400 MHz, CDCl3) δ 4.18 (m, 2H), 3.88 (m, 1H), 3.56 (m, 
6H), 2.76 (m, 2H), 2.63 (m, 2H), 2.26 (s, 6H), 1.56 (m, 2H), 1.25 (m, 22H), 1.19 (m, 
12H), 0.88 (t, J = 6.5 Hz, 3H); 31P -NMR (300 MHz, CDCl3) δ 150.1. 
2,3-bis(tetradecyloxy)propyl 2-cyanoethyl diisopropylphosphoramidite, 19. Yield: 80%; 
1H-NMR (300 MHz, CDCl3) δ 4.12 (m, 2H), 3.79 (m, 1H), 3.47 (m, 8H), 3.26 (m, 1H), 
2.69 (m, 2H), 2.56 (m, 2H), 1.48 (m, 4H), 1.18 (m, 44H), 1.12 (d, J = 6.7 Hz, 6H), 1.10 
(d, J = 6.7 Hz, 6H), 0.81 (t, J = 6.6 Hz, 6H); 31P -NMR (300 MHz, CDCl3) δ 150.1. 
Oligodeoxynucleotide synthesis.  Oligodeoxynucleotide sequences were prepared using 
solid phase methodology. The syntheses were carried out on an Applied Biosystems 
Model 3400 DNA synthesizer using a 1 μmol scale. Oligonucleotides were purified by 
reversed-phase HPLC, as described above. Mass spectrometry of modified dodecamers: 
20 [5’-d(CGCGAATTCGCG)-C14-3’] found 3994, expected 3996; 21 [5’-
d(CGCGAATTCGCG)-C18-3’]: found 4045, expected 4048; 22 [C28-5’-
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d(CGCGAATTCGCG)-3’]: found 4196, expected 4192; 23 [C14N-5’-
d(CGCGAATTCGCG)-3’]: found 4028, expected 4025.  
Oligoribonucleotides. The following RNA sequences were obtained from commercial 
sources (Sigma-Proligo, Dharmacon): passenger scrambled 5’-CAG UCG CGU UUG 
CGA CUG G-dT-dT-3’; guide scrambled 5’-CCA GUC GCA AAC GCG ACU G-dT-
dT-3’, guide anti-TNFα: 5’-GAG GCU GAG ACA UAG GCA C-dT-dT-3’ and 
passenger anti-TNFα: 5’-GUG CCU AUG UCU CAG CCU C-dT-dT-3’. RNA 
monomers in capital letters, dT represents thymidine. The 3’-cholesterol passenger anti-
TNFα: strand 5’-GUG CCU AUG UCU CAG CCU C-dT-dT-3’-cholesterol was 
prepared using the cholesterol-tetraethyleneglycol (TEG)-3’-CPG support from 
commercial sources (Glen Research). 
Oligoribonucleotides were prepared on a DNA synthesizer (Applied Biosystems 3400) 
using 2-cyanoethyl phosphoramidites. The following solutions were used: 0.4 M 1H-
tetrazol in ACN (activation); 3% trichloroacetic acid in DCM (detritylation), acetic 
anhydride / pyridine / tetrahydrofurane (1: 1: 8) (capping A), 10 % N-methylimidazole 
in tetrahydrofurane (capping B), 0.01 M iodine in tetrahydrofurane / pyridine / water (7: 
2: 1) (oxidation). Guanosine was protected with the dimethylaminomethylidene group, 
cytidine was protected with the acetyl group and adenosine with the benzoyl group. The 
2’-OH protecting group for the RNA monomers was the t-butyldimethylsilyl (TBDMS) 
group. The average coupling yield was around 97-98% per step. Modified RNA strands 
were purified using DMT-on based protocols: RNAs were cleaved from the support 
with a mixture of concentrated ammonia and ethanol 3:1 at 55 ºC for 60 minutes. The 
solvent was evaporated to dryness and a 1M solution of TBAF in THF was added. 
RNAs were incubated for 24 hours at room temperature. The deprotection reaction was 
quenched and modified RNA conjugates were desalted (Sephadex, NAP-10) and 
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purified by semi-preparative HPLC. DMTr groups were then deprotected (AcOH 80%, 
30 min) and extracted them with ether. Finally, chemically modified RNA conjugates 
were desalted (Sephadex, NAP-5). 
Melting experiments on siRNA duplexes. A 100 mM potassium acetate, 2 mM 
magnesium acetate and 30 mM HEPES-KOH solution at pH = 7.4 at a final 
concentration of approximately 0.25 OD for each strand was used for the melting 
experiments. The solutions were heated to 90ºC and allowed to cool slowly to room 
temperature. Melting curves were recorded using a concentration of approximately 1 
mM for each strand in 1 mL of the tested solution in Teflon-stoppered quartz cuvettes of 
1 cm optical path length. The melting temperatures were determined as the maxima of 
the first derivative of absorbance versus temperature. In all cases, the complexes 
displayed sharp, apparently two-state transitions. The data were analyzed by the 
denaturation curve-processing program. 
Table 2 
 
Annealing of the siRNA duplexes. Equimolar amounts of the corresponding passenger 
and guide strands were dissolved in a buffer containing 10 mM TRIS 50 mM NaCl 
(100µL) and annealed in a final volume of 100 µL. The solutions of siRNAs were 
heated at 94ºC for two minutes and allowed to cool until they reached room 
temperature. Then, 3M NaOAc pH = 5.2 were added (10 µL) along with EtOH (96%) 
(275 µL). Samples were stirred, centrifuged at 4ºC (15 minutes, 12000 rpm) and 
precipitated at -20ºC. Finally, the supernatant was removed and the respective pellets 
were carefully dried under argon. 
Cell culture and siRNA conjugates treatments. PROTOCOL A (transfection of lipid-
siRNA conjugates using Oligofectamine): HeLa cells were cultured under standard 
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conditions (37ºC, 5% CO2, Dulbecco’s Modified  Eagle Medium, 10% fetal bovine 
serum, 2 mM l-glutamine, supplemented with penicillin (100 U/mL) and streptomycin 
(100 mg/mL). All experiments were conducted at 40–60% confluence. HeLa cells were 
transfected with 250 ng of murine expressing TNF-α plasmid using lipofectin 
(Invitrogen), according to the manufacturer’s instructions. One hour after transfection, 
m-TNF-α expressing HeLa cells were then transfected with unmodified siRNA-1 and 
modified (siRNA-2, siRNA-3, siRNA-4, siRNA-5, siRNA-6, siRNA-7, siRNA-9, or 
siRNA-10) and a scrambled sequence siRNA-8 at 50nM per well against TNF-α using 
oligofectamine (Invitrogen). The TNF-α concentration was determined from cell culture 
supernatant by an enzyme-linked immunoabsorbent assay kit (Bender MedSystems) 
following the manufacturer’s instructions. 
PROTOCOL B (transfection of lipid-siRNA conjugates s in the absence of 
Oligofectamine): HeLa cells were co-transfected with murine expressing TNF-α 
plasmid as in the protocol A. One hour later, lipid-siRNA conjugates (siRNA-2, siRNA-
3, siRNA-4, siRNA-5, siRNA-6 and siRNA-7) and a scrambled sequence siRNA-8 at 
100nM were added. The TNF-α concentration was determined from cell culture 
supernatant by an enzyme-linked immunoabsorbent assay kit (Bender MedSystems), 
following the manufacturer’s instructions. 
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LEGENDS 
 
Scheme 1. Synthesis of lipid-functionalized CPG solid supports 5 and 10 used for the 
preparation of DNA/RNA molecules carrying lipids at the 3’-position. Reagents and 
Conditions: (a) NaH (60%), 1-Bromotetradecane or 6, toluene, reflux, overnight, 2 
(78%), 7 (77%); (b) pTsOH, MeOH, r.t., overnight, 3 (72%), 8 (70%); (c) MMTr-Cl, 
DMAP, pyridine, 40ºC, overnight, 4 (80%), 9 (67%); (d) CPG derivatization. 
 
Scheme 2. Synthesis of lipophosphoramidites 15 and 19 to be introduced into 
DNA/RNA molecules at the 5’-position. Reagents and Conditions: For 
lipophosphoramidite 15: (a) Trityl chloride (reference 42); (b) NaH (60%), THF, reflux, 
overnight; 76%; (c) DCM:TFA 20%, r.t., 2 h, 76%; (d) NC(CH2)2OP(iPr2N)Cl, DIEA, 
DCM, 0ºC to r.t., 1h 30 min. For lipophosphoramidite 19: (a) 1-bromotetradecane 
(reference 36); (b) Pd[(PPh3)]4, N, N- dimethylbarbituric acid, THF, 90ºC, sealed tube, 
overnight, 97%; (c) NC(CH2)2OP(iPr2N)Cl, DIEA, DCM, 0ºC to r.t., 1h 30 min 
 
Figure 1. Proposed lipid modifications to be introduced into DNA and RNA molecules. 
(a) Selected lipids were introduced at the 3’-termini and (b) selected lipids were 
introduced at the 5’-termini. 
 
Figure 2. Plot of gene-specific silencing activities for unmodified (siRNA-1), modified 
(siRNA-2, siRNA-3, siRNA-4, siRNA-5, siRNA-6, siRNA-7 and siRNA-8) conjugates 
along with a scrambled sequence Scr (50 nM per well). Transfection of siRNA 
conjugates was carried out using Oligofectamine (Protocol A). Values are represented 
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as the average ±ES, n = 3 and are compared to a scrambled sequence. ***p<0.001, 
ANOVA Test, Bonferrini post-test. 
 
Figure 3. Plot of gene-specific silencing activities for unmodified (siRNA-1) and 
modified (siRNA-2, siRNA-3, siRNA-4, siRNA-5, siRNA-6 and siRNA-7) lipid-siRNA 
conjugates along with a scrambled sequence siRNA-8 at 100 nM without transfecting 
agent (Protocol B). 
 
Figure 4. Plot of gene-specific silencing activities for unmodified (siRNA-1) and 
modified (siRNA-9 and siRNA-10) lipid-siRNA conjugates along with a scrambled 
siRNA-8 at 50 nM with transfecting agent (Protocol A). 
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Table 1. Modified and Unmodified RNA Sequences Used for the Preparation of the 
Corresponding siRNA Conjugates for RNA Interference Studies. 
Compound 
number 
Lipida Sequence (5’-3’)b MSc siRNAd 
24 
 
None 
P, wt 
GUG CCU AUG UCU CAG CCU 
C-dT-dT 
n. d. 
siRNA-1 
25 Chole, P GUG CCU AUG UCU CAG CCU 
C-dT-dT-Chol 
7319 / 
7310 
siRNA-2 
26 C14-3’, 
P 
GUG CCU AUG UCU CAG CCU 
C-dT-dT-C14 
6909 / 
6908 
siRNA-3 
27 C14-3’f, 
P 
GUG CCU AUG UCU CAG CCU 
C-dT-dT-C14 
7013 
[M+Na+]  / 
6993 
siRNA-4 
28 C18-3’, 
P 
GUG CCU AUG UCU CAG CCU 
C-dT-dT-C18 
6964 / 
6961 
siRNA-5 
29 C14N-5’ 
P 
C14N-GUG CCU AUG UCU CAG 
CCU C-dT-dT 
6934 / 
6937 
siRNA-6 
30 C28N-5’ 
P 
C28-GUG CCU AUG UCU CAG 
CCU C-dT-dT 
7112 / 
7106 
siRNA-7 
31 None 
P, scr 
CAG UCG CGU UUG CGA CUG 
G-dT-dT 
n. d. 
siRNA-8 
32 C14-3’, 
G 
GAG GCU GAG ACA UAG GCA 
C-dT-dT-C14 
7123 / 
7120 
siRNA-9 
33 C18-3’, 
G 
GAG GCU GAG ACA UAG GCA 
C-dT-dT-C18 
7176 / 
7174 
siRNA-
10 
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awt: wild type, P: passenger strand, G: guide strand, scr: scrambled, bRNA monomers 
are in uppercase letters, dT stands for thymidine. cMass spectra (found / expected). 
dsiRNA were prepared by hybridization with the corresponding guide strands (24-30 
with 5’-GAG GCU GAG ACA UAG GCA C-dT-dT-3’, 31 with 5’-CCA GUC GCA 
AAC GCG ACU G-dT-dT-3’ and 32 and 33 with 5’-GUG CCU AUG UCU CAG CCU 
C-dT-dT-3’). esiRNA conjugate with cholesterol at the 3’-termini was prepared for 
comparison purposes. fRNA with underline contains 2’-O-methyl-RNA monomers. n.d. 
not determined. 
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Table 2. Melting Temperatures (ºC) of the siRNA Conjugates Prepared in this Study.a 
siRNA Lipid Tm (DTmb) 
siRNA-1 None 83.5 
siRNA-3 C14-3’ 83.9 (0.4) 
siRNA-4 C14-3’ 86.9 (3.4) 
siRNA-5 C18-3’ 83.6 (0.1) 
siRNA-6 C28-5’ 84.3 (0.8) 
aConditions: 100 mM potassium acetate, 2 mM magnesium acetate and 30 mM HEPES-
KOH solution at pH 7.4. bDTm is the difference between the melting temperature of the 
lipid siRNA minus the melting temperature of the corresponding unmodified siRNA. 
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